Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Collegium Pharmaceutical (COLL) Debt to Equity (2016 - 2025)

Collegium Pharmaceutical has reported Debt to Equity over the past 10 years, most recently at $1.86 for Q4 2025.

  • Quarterly results put Debt to Equity at $1.86 for Q4 2025, down 26.76% from a year ago — trailing twelve months through Dec 2025 was $1.86 (down 26.76% YoY), and the annual figure for FY2025 was $1.86, down 26.76%.
  • Debt to Equity for Q4 2025 was $1.86 at Collegium Pharmaceutical, down from $2.07 in the prior quarter.
  • Over the last five years, Debt to Equity for COLL hit a ceiling of $3.2 in Q1 2022 and a floor of $0.49 in Q3 2021.
  • Median Debt to Equity over the past 5 years was $2.48 (2023), compared with a mean of $2.09.
  • Biggest five-year swings in Debt to Equity: crashed 54.46% in 2021 and later soared 508.57% in 2022.
  • Collegium Pharmaceutical's Debt to Equity stood at $0.54 in 2021, then surged by 430.2% to $2.87 in 2022, then fell by 27.9% to $2.07 in 2023, then increased by 22.22% to $2.53 in 2024, then dropped by 26.76% to $1.86 in 2025.
  • The last three reported values for Debt to Equity were $1.86 (Q4 2025), $2.07 (Q3 2025), and $2.52 (Q2 2025) per Business Quant data.